Minerva Neurosciences (NASDAQ:NERV – Get Free Report) and Relmada Therapeutics (NASDAQ:RLMD – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.
Volatility and Risk
Minerva Neurosciences has a beta of -0.31, indicating that its stock price is 131% less volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Minerva Neurosciences and Relmada Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Minerva Neurosciences | 1 | 1 | 0 | 0 | 1.50 |
| Relmada Therapeutics | 1 | 1 | 4 | 1 | 2.71 |
Insider and Institutional Ownership
34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 10.4% of Minerva Neurosciences shares are held by insiders. Comparatively, 20.7% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Minerva Neurosciences and Relmada Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Minerva Neurosciences | N/A | -41.35% | -35.62% |
| Relmada Therapeutics | N/A | -170.83% | -145.58% |
Valuation and Earnings
This table compares Minerva Neurosciences and Relmada Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Minerva Neurosciences | N/A | N/A | -$293.42 million | ($26.80) | -0.23 |
| Relmada Therapeutics | N/A | N/A | -$57.38 million | ($1.45) | -4.51 |
Relmada Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Relmada Therapeutics beats Minerva Neurosciences on 9 of the 12 factors compared between the two stocks.
About Minerva Neurosciences
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
About Relmada Therapeutics
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
